MaltSci 麦伴科研

Appearance

Popular Reports / hematology

This report is written by MaltSci based on the latest literature and research findings

What are the mechanisms of blood clotting disorders? ​

Abstract ​

Blood clotting disorders pose a major public health challenge, affecting millions globally and resulting in severe complications such as excessive bleeding and thrombosis. These disorders encompass a range of conditions characterized by abnormal clot formation or dissolution, leading to life-threatening events like stroke and heart attack. Understanding the underlying mechanisms of these disorders is critical for developing effective treatment strategies. This review provides a comprehensive overview of the blood coagulation process, including the coagulation cascade, key factors and cells involved in hemostasis, and the genetic and environmental influences on clotting disorders. It highlights the complexities of inherited conditions like hemophilia and von Willebrand disease, as well as the mechanisms contributing to thrombophilia. Recent advancements in gene therapy and novel anticoagulant medications represent significant progress in the field, offering new hope for patients affected by these disorders. By synthesizing current knowledge, this report aims to enhance understanding and inform future research, ultimately improving clinical outcomes for individuals with blood clotting disorders.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Overview of Blood Coagulation
    • 2.1 The Coagulation Cascade
    • 2.2 Key Factors and Cells Involved in Hemostasis
  • 3 Genetic Factors in Blood Clotting Disorders
    • 3.1 Inherited Coagulation Disorders
    • 3.2 Genetic Mutations and Their Impact
  • 4 Environmental and Acquired Factors
    • 4.1 Lifestyle Influences on Clotting
    • 4.2 Disease States and Medications Affecting Coagulation
  • 5 Pathophysiology of Common Clotting Disorders
    • 5.1 Hemophilia A and B
    • 5.2 von Willebrand Disease
    • 5.3 Thrombophilia
  • 6 Novel Therapeutic Approaches
    • 6.1 Advances in Gene Therapy
    • 6.2 New Anticoagulant Medications
  • 7 Summary

1 Introduction ​

Blood clotting disorders are a significant public health concern that affect millions of individuals worldwide, leading to severe complications such as excessive bleeding, thrombosis, and associated cardiovascular events. These disorders encompass a range of conditions characterized by abnormal clot formation or dissolution, often resulting in life-threatening situations such as stroke, heart attack, and venous thromboembolism. The complexities of the hemostatic process, which involves intricate interactions between platelets, coagulation factors, and the vascular system, highlight the importance of understanding the underlying mechanisms of these disorders. A comprehensive exploration of the pathophysiology, genetic predispositions, and environmental influences on blood clotting is essential for developing effective treatment strategies and improving patient outcomes.

The significance of researching blood clotting disorders lies not only in their prevalence but also in their impact on healthcare systems globally. With advancements in our understanding of hemostasis and thrombosis, there is a growing recognition of the need for personalized medicine approaches that take into account individual risk factors and genetic backgrounds. Furthermore, the ongoing emergence of novel therapeutic options, including gene therapies and new anticoagulants, necessitates a thorough review of current knowledge to guide clinical practice and future research endeavors.

Current research in the field of blood coagulation has elucidated various mechanisms involved in hemostasis and thrombosis. The coagulation cascade, a series of enzymatic reactions leading to fibrin formation, is a focal point of study, with key insights into the roles of different coagulation factors and cells, such as platelets, in maintaining vascular integrity [1]. Moreover, emerging studies have highlighted the mechanical properties of blood clots, emphasizing the dynamic interactions between platelets and fibrin networks during clot formation and contraction [2][3]. These insights reveal that blood clots are not merely passive structures but are actively remodeled by the forces exerted by platelets, which play a crucial role in both normal hemostasis and pathological conditions [3].

This review will systematically address the mechanisms underlying blood clotting disorders, organized into several key sections. The first section will provide an overview of the blood coagulation process, detailing the coagulation cascade and the essential factors and cells involved in hemostasis. Following this, we will delve into the genetic factors contributing to inherited blood clotting disorders, including specific genetic mutations and their clinical implications. The review will then explore environmental and acquired factors, examining how lifestyle choices and medical conditions can influence coagulation pathways. Subsequently, we will discuss the pathophysiology of common clotting disorders, such as hemophilia, von Willebrand disease, and thrombophilia, highlighting their clinical presentations and management challenges. Finally, we will present novel therapeutic approaches, including advancements in gene therapy and the development of new anticoagulant medications, which represent the forefront of research aimed at mitigating the impact of these disorders.

By synthesizing the current understanding of blood clotting disorders, this report aims to provide a comprehensive overview that is beneficial for clinicians, researchers, and students alike. The insights gained from this review will contribute to a deeper understanding of the complexities of hemostasis and thrombosis, ultimately guiding future research and improving clinical outcomes for individuals affected by these challenging conditions.

2 Overview of Blood Coagulation ​

2.1 The Coagulation Cascade ​

The mechanisms of blood clotting disorders are intricately linked to the processes involved in the coagulation cascade, which consists of a series of enzyme activation events leading to the formation of a blood clot. The plasma coagulation system in mammals operates through the activation of serine proteases that convert proenzymes and procofactors into active forms via limited proteolysis. This cascade ultimately results in the polymerization of fibrin and the activation of platelets, essential for forming a stable blood clot that prevents excessive blood loss following vascular injury, a process known as normal hemostasis (Smith et al. 2015) [1].

However, disruptions in this finely tuned system can lead to various blood clotting disorders. Pathological conditions such as thrombosis arise when the coagulation system is excessively activated, leading to unwanted blood clots within blood vessels. These clots can obstruct blood flow, resulting in serious health complications such as ischemic stroke and venous thromboembolism. The two primary mechanisms that initiate blood clotting are the tissue factor pathway and the contact pathway. The tissue factor pathway is predominantly responsible for normal hemostasis, while both pathways may contribute to thrombotic events. Emerging research suggests that the contact pathway may also play a role in host defense against pathogens (Smith et al. 2015) [1].

In addition to these mechanisms, inherited disorders of platelet function can significantly impact clotting. For instance, Glanzmann thrombasthenia, an autosomal recessive disorder, is characterized by a defect in the platelet integrin alphaIIbbeta3, leading to impaired platelet aggregation and a heightened risk of bleeding (Israels et al. 2010) [4]. The study of such inherited conditions has shed light on the structural and functional abnormalities in platelets that contribute to bleeding diatheses.

Moreover, the mechanical properties of blood clots, which are influenced by the dynamic forces exerted by platelets, are crucial in understanding the pathophysiology of clotting disorders. As platelets contract and rearrange within the clot, they alter its material properties, which can be linked to various bleeding and clotting disorders, including cancer and ischemic heart disease (Williams et al. 2019) [3].

Overall, blood clotting disorders arise from a complex interplay of biochemical cascades, mechanical forces, and inherited abnormalities, necessitating a multifaceted approach to diagnosis and treatment. Understanding these mechanisms is essential for developing effective therapeutic strategies to manage both bleeding and thrombotic conditions.

2.2 Key Factors and Cells Involved in Hemostasis ​

Blood coagulation is a complex physiological process that involves a cascade of enzyme activation events leading to the formation of a stable blood clot. This process is critical for preventing excessive blood loss following vascular injury, termed hemostasis. However, various disorders can impair this process, leading to bleeding complications or pathological thrombosis.

The plasma coagulation system comprises two main pathways: the tissue factor pathway and the contact pathway. The tissue factor pathway is primarily responsible for normal hemostasis, while both pathways contribute to thrombosis. The initiation of the clotting cascade involves serine proteases that activate proteins (proenzymes and procofactors) through limited proteolysis, ultimately resulting in fibrin polymerization and platelet activation [1].

Platelets play a pivotal role in hemostasis. Upon vascular injury, platelets adhere to subendothelial matrix proteins, leading to their activation, spreading, aggregation, and the recruitment of additional platelets to form a primary hemostatic plug. This plug serves as a surface for thrombin generation, which is crucial for fibrin mesh formation that stabilizes the clot [4]. Inherited disorders of platelet function can significantly disrupt these processes. For instance, Glanzmann thrombasthenia, caused by a defect in the platelet integrin alphaIIbbeta3, results in absent platelet aggregation and severe bleeding diathesis [4].

Moreover, blood clotting disorders can be categorized into two main types: bleeding disorders and thrombotic disorders. Bleeding disorders, such as hemophilia, are characterized by deficiencies in specific clotting factors, leading to impaired clot formation. In contrast, thrombotic disorders involve excessive clot formation within blood vessels, which can lead to ischemic events such as stroke or venous thromboembolism [2].

The mechanical properties of blood clots are also essential in understanding clotting disorders. Research has shown that the contraction of blood clots, which is driven by the interactions between platelets and fibrin, is crucial for the structural integrity of the clot. Impairment in this contraction process can lead to complications associated with both bleeding and thrombotic conditions [2]. The mechanical forces exerted by platelets significantly influence the stiffness and overall properties of the clot, linking the mechanics of clotting to various diseases [3].

In summary, blood coagulation disorders arise from a variety of mechanisms, including genetic defects in platelet function, deficiencies in clotting factors, and disruptions in the biomechanical processes governing clot contraction. Understanding these mechanisms is critical for developing effective diagnostic and therapeutic strategies for managing bleeding and thrombotic disorders.

3 Genetic Factors in Blood Clotting Disorders ​

3.1 Inherited Coagulation Disorders ​

Blood clotting disorders can be attributed to a variety of mechanisms, particularly involving genetic factors that influence the hemostatic balance. The pathophysiology of these disorders often indicates a multi-causal nature, where both genetic and acquired factors interact to modulate clinical outcomes. Inherited coagulation disorders, such as hemophilia A and B, primarily arise from deficiencies in specific coagulation factors, leading to a predisposition to bleeding. These disorders are inherited as X-linked recessive traits, with hemophilia A caused by a deficiency in factor VIII and hemophilia B resulting from a deficiency in factor IX.

Recessively inherited coagulation disorders, although rarer, involve deficiencies of coagulation factors other than factor VIII and IX. These disorders are inherited as autosomal recessive traits, with a prevalence ranging from 1 in 500,000 to 1 in 2 million for homozygous forms. The types and severity of bleeding symptoms associated with these deficiencies are not as well established as for hemophilia A and B, necessitating a comprehensive understanding of the genetic basis, clinical manifestations, and management strategies for these conditions [5].

Additionally, hypercoagulable states represent another category of blood clotting disorders characterized by an increased risk for thromboembolism. These can be inherited or acquired and involve a disordered thromboregulation. Inherited conditions may include deficiencies in inhibitors such as antithrombin III, protein C, and protein S, which are critical for maintaining the balance between coagulation and anticoagulation. Acquired hypercoagulable states may result from various factors, including endothelial activation by cytokines that convert normal vessel-wall anticoagulant functions to a proinflammatory thrombogenic phenotype [6].

The genetic factors that influence the expression of these coagulation disorders play a significant role in their clinical implications. For instance, the interaction of multiple genetic factors can either attenuate clinical symptoms or synergistically worsen them, leading to a higher risk than would be expected from the separate effects of individual factors [7]. Furthermore, advancements in genomic approaches have enhanced the understanding of these disorders, with next-generation sequencing becoming increasingly important in identifying genetic mutations responsible for bleeding and thrombotic disorders [8].

In summary, the mechanisms underlying blood clotting disorders are complex and multifaceted, involving a range of genetic factors that contribute to both bleeding and thrombotic tendencies. The study of these mechanisms is essential for developing effective diagnostic and therapeutic strategies to manage these conditions.

3.2 Genetic Mutations and Their Impact ​

Blood clotting disorders are complex conditions that arise from a combination of genetic and environmental factors. Genetic mutations play a crucial role in the pathophysiology of these disorders, affecting the hemostatic balance and leading to either bleeding or thrombosis.

The genetic basis of thrombosis, for instance, has been extensively studied, highlighting that both loss-of-function mutations in natural anticoagulants and gain-of-function mutations in procoagulant factors are significant contributors to venous thrombosis (VT). Notably, mutations in antithrombin, protein C, and protein S lead to a deficiency in natural anticoagulants, whereas mutations such as FV Leiden and prothrombin G20210A enhance procoagulant activity, thereby increasing thrombotic risk. This dual mechanism underlines the complexity of genetic influences on coagulation disorders (Bafunno & Margaglione, 2010) [9].

Additionally, the interplay of multiple genetic factors can modulate the phenotypic expression of these disorders. The interaction of genetic predispositions with acquired factors can either exacerbate or attenuate clinical symptoms. For example, the synergistic effects of different genetic mutations may result in a higher risk of thrombosis than would be expected from the individual effects of each mutation alone (Franchini & Mannucci, 2009) [7].

Moreover, the identification of mutations within the coagulation factor IX (F9) locus in hemophilia B exemplifies how specific genetic alterations can directly impact clotting ability. Mutations in the promoter region of F9 can significantly alter gene expression, demonstrating the profound implications of regulatory mutations on the severity of bleeding disorders (Funnell & Crossley, 2014) [10].

Advancements in genomic approaches have further enhanced the understanding of bleeding disorders. While significant progress has been made in diagnosing common inherited bleeding disorders like hemophilia A and B, the genetic characterization of rare bleeding disorders remains less developed. Many of these disorders are linked to mutations in coding regions or splice sites of relevant genes. However, in a subset of patients, no identifiable genetic defect is found, highlighting the necessity for innovative genomic technologies and bioinformatics analysis to uncover underlying genetic causes (Peyvandi & Hayward, 2016) [8].

In summary, the mechanisms underlying blood clotting disorders are multifaceted, involving various genetic mutations that disrupt the delicate balance of hemostasis. The identification and understanding of these genetic factors are essential for improving diagnosis, treatment, and management of patients with clotting disorders.

4 Environmental and Acquired Factors ​

4.1 Lifestyle Influences on Clotting ​

The knowledge base information is insufficient. Please consider switching to a different knowledge base or supplementing relevant literature.

4.2 Disease States and Medications Affecting Coagulation ​

Blood clotting disorders are complex conditions influenced by a combination of genetic and acquired factors. The pathophysiology of hemostasis reveals that these disorders can arise from multiple causal interactions, where both genetic predispositions and environmental influences play significant roles.

Acquired factors contributing to bleeding disorders often include age-related changes in hemostatic balance. For instance, in the elderly, the hemostatic system undergoes alterations due to factors such as increased platelet activation, changes in clotting factor proteins, and modifications in the fibrinolytic system. These changes generally predispose older individuals to thrombosis rather than bleeding, yet they may necessitate antiplatelet or anticoagulation therapies, which paradoxically heighten the risk of bleeding complications in this population (Kruse-Jarres 2015) [11].

Furthermore, the interaction of genetic and acquired factors can lead to a synergistic effect, exacerbating the clinical manifestations of coagulation disorders. For example, certain genetic polymorphisms may influence the risk of developing arterial thrombi, particularly in the context of atherosclerotic plaque injury. The formation of arterial thrombi is primarily characterized by platelet aggregation under high blood flow conditions, leading to the development of 'white clots' that are stabilized by fibrin (Lippi et al. 2011) [12].

Medications also significantly impact coagulation dynamics. The use of anticoagulants and nonsteroidal anti-inflammatory drugs (NSAIDs) is prevalent in treating various conditions, especially in the elderly. These medications can complicate the management of bleeding disorders, as they can increase the likelihood of bleeding due to altered hemostatic function (Kruse-Jarres 2015) [11].

In addition, understanding the fluid mechanics of blood clot formation reveals that hydrodynamic forces and fluid-mediated transport are critical in the clotting process. These dynamics can affect how clots form and stabilize, further complicating the picture of coagulation disorders (Fogelson and Neeves 2015) [13].

Moreover, the genetic landscape underlying coagulation disorders is not entirely understood, particularly concerning arterial thrombosis. Although hereditary risk factors for venous thrombosis are well-documented, the genetic contributions to arterial thrombosis require further exploration to establish a comprehensive understanding of these conditions (Anderson et al. 2013) [14].

In summary, blood clotting disorders arise from a multifaceted interplay of genetic and acquired factors, with environmental influences and medications further modulating coagulation pathways. This complexity necessitates a nuanced approach to diagnosis and treatment, particularly in populations with increased vulnerability, such as the elderly.

5 Pathophysiology of Common Clotting Disorders ​

5.1 Hemophilia A and B ​

Hemophilia A and B are inherited X-linked disorders caused by deficiencies in coagulation factors, specifically factor VIII (FVIII) for hemophilia A and factor IX (FIX) for hemophilia B. These deficiencies lead to a significant bleeding tendency, which can manifest as spontaneous bleeding or excessive bleeding following trauma or surgical procedures. The severity of the bleeding tendency is proportional to the level of the deficient clotting factor; patients with severe hemophilia typically have undetectable levels of FVIII or FIX, while those with mild forms may retain 2% to 40% of normal factor levels, experiencing bleeding primarily after trauma or surgery [15].

The pathophysiology of hemophilia involves several mechanisms that contribute to the bleeding diathesis. Firstly, the absence or dysfunction of FVIII or FIX disrupts the coagulation cascade, which is essential for effective hemostasis. In normal hemostasis, FVIII acts as a cofactor for FIX, enhancing its activity in the conversion of prothrombin to thrombin, a crucial step in the formation of fibrin clots. The lack of these factors results in impaired thrombin generation, leading to inadequate fibrin formation and a resultant inability to form stable blood clots [16].

In addition to the deficiency of clotting factors, patients with hemophilia may also exhibit abnormalities in platelet function. While primary hemostasis, which involves platelet aggregation and activation, is generally considered normal, some studies have reported prolonged bleeding times in hemophilia patients, suggesting potential alterations in platelet function. These alterations may include increased platelet P-selectin expression and reduced aggregation upon exposure to tissue factor, which could contribute to the variability in bleeding tendencies observed among individuals with similar factor levels [16].

Moreover, the interaction between aging and treatment-related factors has been recognized as a significant contributor to thrombotic complications in hemophilia patients. As the management of hemophilia has improved over the past decades, the life expectancy of these patients has increased, which may expose them to additional thrombotic risks associated with aging [17].

The understanding of hemophilia has evolved with the advent of new therapeutic strategies, including gene therapy aimed at achieving sustained expression of FVIII or FIX to correct the underlying deficiency. However, achieving adequate factor levels to prevent bleeding remains a challenge, and the immune response to gene therapy vectors can pose additional risks [18].

In summary, the mechanisms underlying hemophilia A and B involve a complex interplay of coagulation factor deficiencies, potential platelet dysfunction, and the impact of treatment and aging, all of which contribute to the bleeding complications characteristic of these disorders. Continued research into the pathophysiology of hemophilia is crucial for the development of effective therapies and management strategies.

5.2 von Willebrand Disease ​

Von Willebrand disease (vWD) is recognized as the most prevalent inherited bleeding disorder, with an estimated prevalence of approximately 1% in the general population. The pathophysiology of vWD primarily involves abnormalities in von Willebrand factor (vWF), a multimeric glycoprotein crucial for hemostasis. vWF serves two main functions: it facilitates platelet adhesion to exposed subendothelial surfaces and acts as a carrier for factor VIII, which is essential for normal blood coagulation. Deficiencies or qualitative defects in vWF lead to impaired platelet function and a subsequent increase in bleeding risk [19].

The disease is classified into several types, with type 1 being the most common, characterized by a partial quantitative deficiency of vWF. This type is inherited in an autosomal dominant manner, exhibiting significant variability in penetrance and expressivity [20]. In contrast, type 2 and type 3 vWD involve qualitative defects and complete deficiency of vWF, respectively. The latter two types are less common and typically present with more severe bleeding episodes [21].

The molecular basis of vWD involves specific mutations within the vWF gene, which can lead to the production of dysfunctional vWF proteins. In type 1 vWD, the exact genetic factors contributing to the clinical severity remain largely unknown, with research indicating that various genetic and environmental factors, such as the ABO blood group, age, stress, and pregnancy, can influence the clinical manifestation of the disorder [22].

In clinical practice, the symptoms of vWD often manifest as mucosal bleeding, easy bruising, and increased bleeding during surgical procedures. The severity of these symptoms correlates with the level of vWF and factor VIII in circulation [19]. Diagnostic challenges arise particularly in mild cases, where laboratory measurements may overlap with normal ranges, complicating the identification of affected individuals [20].

Treatment strategies for vWD aim to address both the deficiency of vWF and the associated factor VIII deficiency. Desmopressin (DDAVP) is often effective in type 1 vWD patients who demonstrate a responsive increase in vWF and factor VIII levels following administration. For more severe cases or those unresponsive to DDAVP, vWF/factor VIII concentrates are utilized [19].

In summary, the pathophysiology of von Willebrand disease involves complex interactions between genetic mutations, the functional integrity of vWF, and various physiological factors that together influence bleeding risk and clinical presentation. Understanding these mechanisms is critical for effective diagnosis and management of this common bleeding disorder.

5.3 Thrombophilia ​

Thrombophilia encompasses a range of conditions that predispose individuals to thrombotic events, characterized by an imbalance between procoagulant and anticoagulant factors. The pathophysiology of thrombophilia can be categorized into hereditary and acquired forms, each with distinct mechanisms and risk factors.

Hereditary thrombophilia is associated with genetic mutations that promote hypercoagulability, often due to deficiencies or dysfunctions in natural anticoagulants. For instance, deficiencies in proteins such as antithrombin, protein C, or protein S can lead to increased thrombin generation and a propensity for clot formation. These hereditary factors can create a procoagulant state by preventing the normal regulatory mechanisms that inhibit excessive clotting.

Acquired thrombophilia may arise from various conditions and environmental factors. Autoimmune diseases, cancer, surgical procedures, pregnancy, and the postpartum period can all contribute to a hypercoagulable state. For example, in autoimmune diseases, the inflammatory response can activate the coagulation system, further promoting thrombus formation. Additionally, factors such as obesity and hormonal therapies have been implicated in increasing thrombotic risk due to their effects on the coagulation cascade and vascular health [23].

In the context of hemophilia, a paradoxical scenario arises where patients, typically characterized by bleeding tendencies due to deficiencies in coagulation factors VIII or IX, may also experience thrombotic events. This paradox can be attributed to several factors, including the severity of hemophilia, the presence of additional risk factors such as obesity or smoking, and the potential thrombotic effects of clotting factor replacement therapies, which are essential for managing bleeding in these patients [17][24].

The pathophysiology of thrombosis in hemophilia patients is complex and involves an interplay of various factors. Aging and advancements in treatment over the past three decades have also contributed to the increased risk of thromboembolic complications in this population [17]. It is crucial to understand these mechanisms to effectively manage and prevent thrombotic complications in individuals with clotting disorders.

6 Novel Therapeutic Approaches ​

6.1 Advances in Gene Therapy ​

The knowledge base information is insufficient. Please consider switching to a different knowledge base or supplementing relevant literature.

6.2 New Anticoagulant Medications ​

Blood clotting disorders, which encompass both bleeding disorders and thrombotic conditions, arise from various dysfunctions in the coagulation cascade, a complex series of events that lead to the formation of a blood clot. The mechanisms underlying these disorders can be broadly categorized into two main types: those leading to excessive bleeding (hemorrhagic disorders) and those leading to excessive clotting (thrombotic disorders).

Hemorrhagic disorders often stem from deficiencies or dysfunctions in specific clotting factors. For instance, hemophilia A is caused by a deficiency of factor VIII, while hemophilia B is linked to a deficiency of factor IX. These deficiencies hinder the formation of a stable fibrin clot, leading to prolonged bleeding episodes. Advances in coagulation research have facilitated the development of recombinant clotting factors, which serve as replacement therapy for patients with hemophilia, thereby improving their clinical outcomes [25].

On the other hand, thrombotic disorders are characterized by the inappropriate formation of clots within blood vessels, which can lead to conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE). The coagulation cascade is triggered by the interaction of tissue factor with factor VIIa, propagating through factors Xa and IXa, ultimately leading to thrombin generation. Thrombin plays a pivotal role by converting fibrinogen to fibrin, forming the structural basis of a clot [26].

To address these disorders, particularly thrombotic conditions, novel anticoagulant medications have been developed. Traditional anticoagulants, such as warfarin and heparin, have significant limitations, including unpredictable pharmacokinetics and the need for regular monitoring. In contrast, newer oral anticoagulants (NOACs) have emerged, which offer more predictable effects and fewer interactions with food and other medications. These include direct thrombin inhibitors and factor Xa inhibitors, which act at specific points in the coagulation pathway, thereby reducing the risk of thrombosis with a lower incidence of bleeding complications [27].

The development of these new anticoagulants has been driven by a deeper understanding of the coagulation cascade and advances in molecular modeling and drug design. For example, new agents targeting the initiation and propagation phases of coagulation have been designed, such as tissue factor pathway inhibitors and direct factor Xa inhibitors, which aim to provide effective anticoagulation while minimizing adverse effects [26][28].

In summary, blood clotting disorders arise from various mechanisms affecting the coagulation cascade, leading to either excessive bleeding or thrombosis. The evolution of anticoagulant therapies reflects ongoing research aimed at optimizing treatment strategies for these conditions, enhancing patient care and outcomes [25][29].

7 Conclusion ​

The mechanisms underlying blood clotting disorders are multifaceted, involving a complex interplay of genetic, environmental, and physiological factors. This review has highlighted the critical findings regarding the coagulation cascade, the role of platelets, and the impact of genetic mutations on clotting disorders such as hemophilia and von Willebrand disease. Furthermore, the dual nature of thrombophilia, characterized by both inherited and acquired factors, underscores the need for a comprehensive understanding of these conditions to improve clinical outcomes. Current research indicates a significant potential for novel therapeutic approaches, particularly in gene therapy and the development of new anticoagulants, which may revolutionize the management of blood clotting disorders. Future studies should focus on elucidating the intricate interactions between genetic predispositions and environmental influences, as well as the long-term effects of emerging therapies on patient health. Such investigations will be crucial for the advancement of personalized medicine in the field of hemostasis and thrombosis, ultimately leading to better prevention and treatment strategies for affected individuals.

References ​

  • [1] Stephanie A Smith;Richard J Travers;James H Morrissey. How it all starts: Initiation of the clotting cascade.. Critical reviews in biochemistry and molecular biology(IF=6.4). 2015. PMID:26018600. DOI: 10.3109/10409238.2015.1050550.
  • [2] Christian Michael;Francesco Pancaldi;Samuel Britton;Oleg V Kim;Alina D Peshkova;Khoi Vo;Zhiliang Xu;Rustem I Litvinov;John W Weisel;Mark Alber. Combined computational modeling and experimental study of the biomechanical mechanisms of platelet-driven contraction of fibrin clots.. Communications biology(IF=5.1). 2023. PMID:37620422. DOI: 10.1038/s42003-023-05240-z.
  • [3] Evelyn Kendall Williams;Oluwamayokun Oshinowo;Abhijit Ravindran;Wilbur A Lam;David R Myers. Feeling the Force: Measurements of Platelet Contraction and Their Diagnostic Implications.. Seminars in thrombosis and hemostasis(IF=4.1). 2019. PMID:30566972. DOI: 10.1055/s-0038-1676315.
  • [4] S J Israels;M El-Ekiaby;T Quiroga;D Mezzano. Inherited disorders of platelet function and challenges to diagnosis of mucocutaneous bleeding.. Haemophilia : the official journal of the World Federation of Hemophilia(IF=3.0). 2010. PMID:20590875. DOI: 10.1111/j.1365-2516.2010.02314.x.
  • [5] Pier Mannuccio Mannucci;Stefano Duga;Flora Peyvandi. Recessively inherited coagulation disorders.. Blood(IF=23.1). 2004. PMID:15138162. DOI: 10.1182/blood-2004-02-0595.
  • [6] R L Nachman;R Silverstein. Hypercoagulable states.. Annals of internal medicine(IF=15.2). 1993. PMID:8379603. DOI: 10.7326/0003-4819-119-8-199310150-00008.
  • [7] Massimo Franchini;Pier Mannuccio Mannucci. Multiple gene interaction and modulation of hemostatic balance.. Clinical chemistry and laboratory medicine(IF=3.7). 2009. PMID:19824800. DOI: 10.1515/CCLM.2009.331.
  • [8] F Peyvandi;C P M Hayward. Genomic approaches to bleeding disorders.. Haemophilia : the official journal of the World Federation of Hemophilia(IF=3.0). 2016. PMID:27405675. DOI: 10.1111/hae.12998.
  • [9] Valeria Bafunno;Maurizio Margaglione. Genetic basis of thrombosis.. Clinical chemistry and laboratory medicine(IF=3.7). 2010. PMID:21034258. DOI: 10.1515/CCLM.2010.361.
  • [10] Alister P W Funnell;Merlin Crossley. Hemophilia B Leyden and once mysterious cis-regulatory mutations.. Trends in genetics : TIG(IF=16.3). 2014. PMID:24138812. DOI: .
  • [11] Rebecca Kruse-Jarres. Acquired bleeding disorders in the elderly.. Hematology. American Society of Hematology. Education Program(IF=3.2). 2015. PMID:26637727. DOI: 10.1182/asheducation-2015.1.231.
  • [12] Giuseppe Lippi;Massimo Franchini;Giovanni Targher. Arterial thrombus formation in cardiovascular disease.. Nature reviews. Cardiology(IF=44.2). 2011. PMID:21727917. DOI: 10.1038/nrcardio.2011.91.
  • [13] Aaron L Fogelson;Keith B Neeves. Fluid Mechanics of Blood Clot Formation.. Annual review of fluid mechanics(IF=30.2). 2015. PMID:26236058. DOI: 10.1146/annurev-fluid-010814-014513.
  • [14] Julia A Anderson;Wendy Lim;Jeffrey I Weitz. Genetics of coagulation: what the cardiologist needs to know.. The Canadian journal of cardiology(IF=5.3). 2013. PMID:23261321. DOI: .
  • [15] Fabienne Kloosterman;Anne-Fleur Zwagemaker;Amal Abdi;Samantha Gouw;Giancarlo Castaman;Karin Fijnvandraat. Hemophilia management: Huge impact of a tiny difference.. Research and practice in thrombosis and haemostasis(IF=3.4). 2020. PMID:32211572. DOI: 10.1002/rth2.12314.
  • [16] Julia Riedl;Cihan Ay;Ingrid Pabinger. Platelets and hemophilia: A review of the literature.. Thrombosis research(IF=3.4). 2017. PMID:28550758. DOI: 10.1016/j.thromres.2017.05.013.
  • [17] Massimo Franchini;Daniele Focosi;Pier Mannuccio Mannucci. Thrombotic Complications in Hemophilia: An Intricate Conundrum.. Seminars in thrombosis and hemostasis(IF=4.1). 2025. PMID:40341996. DOI: 10.1055/a-2603-0344.
  • [18] Marinee K Chuah;Nisha Nair;Thierry VandenDriessche. Recent progress in gene therapy for hemophilia.. Human gene therapy(IF=4.0). 2012. PMID:22671033. DOI: 10.1089/hum.2012.088.
  • [19] Giancarlo Castaman;Anne Goodeve;Jeroen Eikenboom; . Principles of care for the diagnosis and treatment of von Willebrand disease.. Haematologica(IF=7.9). 2013. PMID:23633542. DOI: 10.3324/haematol.2012.077263.
  • [20] F Rodeghiero. von Willebrand disease: still an intriguing disorder in the era of molecular medicine.. Haemophilia : the official journal of the World Federation of Hemophilia(IF=3.0). 2002. PMID:12010426. DOI: 10.1046/j.1365-2516.2002.00611.x.
  • [21] S R Lethagen. Pathogenesis, clinical picture and treatment of von Willebrand's disease.. Annals of medicine(IF=4.3). 1995. PMID:8652143. DOI: 10.3109/07853899509019250.
  • [22] D Ginsburg. The molecular biology of von Willebrand disease.. Haemophilia : the official journal of the World Federation of Hemophilia(IF=3.0). 1999. PMID:23401896. DOI: 10.1046/j.1365-2516.1999.0050s2019.x.
  • [23] Benjamín Rubio-Jurado;Paulina Iñiguez-Franco;Pedro A Reyes;Gustavo Robles;Mario Salazar-Páramo;Guadalupe Zavala-Cerna;Carlos Riebeling;Arnulfo Nava. The clinical significance of coagulation and the inflammatory response in autoimmunity.. Clinical reviews in allergy & immunology(IF=11.3). 2012. PMID:21221848. DOI: 10.1007/s12016-010-8240-0.
  • [24] Oana Viola Badulescu;Minerva Codruta Badescu;Iris Bararu Bojan;Maria Vladeanu;Nina Filip;Stefan Dobreanu;Razvan Tudor;Bogdan-Mihnea Ciuntu;Adelina Tanevski;Manuela Ciocoiu. Thrombotic Disease in Hemophilic Patients: Is This a Paradox in a State of Hypocoagulability?. Diagnostics (Basel, Switzerland)(IF=3.3). 2024. PMID:38337802. DOI: 10.3390/diagnostics14030286.
  • [25] H Saito;T Matsushita;T Kojima. Historical perspective and future direction of coagulation research.. Journal of thrombosis and haemostasis : JTH(IF=5.0). 2011. PMID:21781272. DOI: 10.1111/j.1538-7836.2011.04362.x.
  • [26] Jeffrey I Weitz;Mark A Crowther. New anticoagulants: current status and future potential.. American journal of cardiovascular drugs : drugs, devices, and other interventions(IF=3.0). 2003. PMID:14727932. DOI: 10.2165/00129784-200303030-00006.
  • [27] Gidon Ellis;Alan John Camm;Soumendra N Datta. Novel anticoagulants and antiplatelet agents; a guide for the urologist.. BJU international(IF=4.4). 2015. PMID:25808010. DOI: 10.1111/bju.13131.
  • [28] Jeffrey I Weitz;Jack Hirsh;Meyer M Samama. New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.. Chest(IF=8.6). 2004. PMID:15383475. DOI: 10.1378/chest.126.3_suppl.265S.
  • [29] Joo Hee Kim;Kyung-Min Lim;Hye Sun Gwak. New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.. Biomolecules & therapeutics(IF=3.2). 2017. PMID:28365976. DOI: 10.4062/biomolther.2016.271.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Blood Clotting Disorders · Coagulation Mechanisms · Genetic Factors · Novel Anticoagulants · Gene Therapy

© 2025 MaltSci